Skip to content
OpenCapital
Get started

BioMarin Pharmaceuticals BMRN Accounts payable and other current liabilities (Note 11)

Accounts payable and other current liabilities (Note 11) at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's accounts payable and other current liabilities (note 11).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's accounts payable and other current liabilities (note 11)?
BioMarin Pharmaceuticals (BMRN) reported accounts payable and other current liabilities (note 11) of $793.15M in Q1 2026.
How has BioMarin Pharmaceuticals's accounts payable and other current liabilities (note 11) changed year-over-year?
BioMarin Pharmaceuticals's accounts payable and other current liabilities (note 11) increased by 26.3% year-over-year, from $628.21M to $793.15M.
What is the long-term trend for BioMarin Pharmaceuticals's accounts payable and other current liabilities (note 11)?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's accounts payable and other current liabilities (note 11) has grown at a 9.0% compound annual growth rate (CAGR), from $492.55M to $759.03M.